EUVIMEDEUVIMED entdecken
Crossref

Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis

Karla Cárdenas-Soto, Xel-Ha Dominguez, Giovanni Cortes, Felix Tsai, Maria Del Mar Saniger, Paola Guraieb-Chahin, Benjamín Torres-Ocatvo, Christopher Gibbons iD, Jeffery W Kelly, Roy Freeman, Alejandra González-Duarte iD

Journal of the Peripheral Nervous System · 2024

DOI: 10.1111/jns.12624 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the Peripheral Nervous System, 2024. Verfasst von Karla Cárdenas-Soto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Instituto Nacional De Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Benzoxazoles, Skin. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Pfizer Global Medical Grants.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ATTR (ATTRv) amyloidosis neuropathy is characterized by progressive sensorimotor and autonomic nerve degeneration secondary to amyloid deposition caused by a misfolded transthyretin protein (TTR). Small nerve fiber neuropathy is an early clinical manifestation of this disease resulting from the dysfunction of the Aδ and C small nerve fibers. Tafamidis, a selective TTR stabilizer, has proven its efficacy in the earlier stages of hATTR.

Objectives

To evaluate the clinical course and utility of cutaneous pathological biomarkers in patients with ATTR amyloidosis treated with tafamidis compared to control patients.

Methods

Forty patients diagnosed with early stages of ATTRv amyloidosis (polyneuropathy disability [PND] scores 0‐II) underwent small and large nerve fiber neurological evaluations, and annual skin biopsies for intraepidermal nerve fiber density (IENFD) and amyloid deposition index (ADI) estimation. Thirty patients were allocated to receive tafamidis, and 10 patients served as controls. Tafamidis pharmacokinetics analysis was performed in patients who received the treatment.

Results

At baseline, 12% of patients in stage PND 0 and 28% in PND I displayed small nerve fiber denervation in the distal thigh, whereas 23% and 38%, respectively, in the distal leg. Similarly, 72% and 84% had amyloid deposition in the distal thigh and 56% and 69% in the distal leg. Following 1 year of treatment, the tafamidis group showed significant clinical improvement compared to the control group, revealed by the following mean differences (1) −9.3 versus −4 points ( p =

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialBenzoxazolesSkinHumansMaleFemaleMiddle AgedAgedBiomarkersPrealbuminAdultTreatment OutcomeNerve Fibers

Stichwörter der Autor:innen

ATTR amyloidosisamyloid depositionintraepidermal nerve fiberpolyneuropathyskin biomarkersskin biopsies

Substanzen

tafamidisBenzoxazolesBiomarkersPrealbumin

Autor:innen und Institutionen

  • Department of Neurology, Instituto Nacional De Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
  • Department of Chemistry, University of Washington, Seattle, Washington, USA.
  • Neurophysiology Department, Hospital Shriners, Mexico City, Mexico.
  • Centro Neurológico, Centro Médico ABC, Mexico City, Mexico.
  • Hospital Medica Sur, Mexico City, Mexico.
  • Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Christopher Gibbons, Alejandra González-Duarte

Förderung

  • Pfizer Global Medical Grants

Zitieren

APA

Cárdenas-Soto, K., Dominguez, X. H., Cortes, G., Tsai, F., Saniger, M. D. M., Guraieb-Chahin, P., Torres-Ocatvo, B., Gibbons, C., Kelly, J. W., Freeman, R., & González-Duarte, A. (2024). Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis. Journal of the Peripheral Nervous System. https://doi.org/10.1111/jns.12624

Vancouver

Cárdenas-Soto K, Dominguez XH, Cortes G, Tsai F, Saniger MDM, Guraieb-Chahin P, et al. Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis. Journal of the Peripheral Nervous System. 2024. doi:10.1111/jns.12624

BibTeX
@article{CrdenasSoto2024,
  author = {Cárdenas-Soto, Karla and Dominguez, Xel-Ha and Cortes, Giovanni and Tsai, Felix and Saniger, Maria Del Mar and Guraieb-Chahin, Paola and Torres-Ocatvo, Benjamín and Gibbons, Christopher and Kelly, Jeffery W and Freeman, Roy and González-Duarte, Alejandra},
  title = {Cutaneous biomarkers of therapeutic efficacy in early treatment of hereditary ATTR amyloid polyneuropathy with tafamidis},
  journal = {Journal of the Peripheral Nervous System},
  year = {2024},
  doi = {10.1111/jns.12624}
}
Kostenlos starten →